Offc Action Outgoing

PYLARIFY

Progenics Pharmaceuticals, Inc.

U.S. Trademark Registration No. 88647018 - PYLARIFY - MIN.629.US

To:	Progenics Pharmaceuticals, Inc. (botrademarks@klgates.com)
Subject:	U.S. Trademark Registration No. 88647018 - PYLARIFY - MIN.629.US
Sent:	07/01/20 04:08:26 PM
Sent As:	ecomitu@uspto.gov
Attachments:

United States Patent and Trademark Office (USPTO)

U.S. Application Serial No. 88647018

Mark: PYLARIFY

Correspondence Address:

Phi Lan M. Tinsley

K&L GATES LLP

ONE LINCOLN STREET

STATE STREET FINANCIAL CENTER

BOSTON, MA 02111

Applicant: Progenics Pharmaceuticals, Inc.

Reference/Docket No. MIN.629.US

Correspondence Email Address:

botrademarks@klgates.com

NOTICE THAT PROCESSING OF

REQUEST TO DIVIDE APPLICATION IS COMPLETED

No Response Required

Issue date: July 1, 2020

The request to divide application serial no. 88647018 filed on June 17, 2020 has been processed as follows:

(1) Parent (original) application serial no. 88647018 contains the following services:

Class 42: Scientific research and development in the nature of research, development and preparation of pharmaceutical drugs and imaging agents for medical use; Providing temporary use of non-downloadable medical imaging software for the identification, quantification, diagnosis, prevention, treatment and monitoring of cancer.

Class 44: Providing medical testing services and information in the field of cancer diagnosis, treatment and prevention; Web-based medical testing for identification, quantification, diagnostic or treatment purposes in the field of cancer; providing medical information in the field of cancer identification, diagnosis, treatment and prevention; medical imaging services.

To avoid abandonment, applicant must continue to file requests for extension of time to file a statement of use (extension requests) or a statement of use within the six-month period after the issuance of the notice of allowance or before expiration of a previously granted extension period. 37 C.F.R. §§2.88(a), 2.89(a)-(b).

(2) Child application serial no. 88978293 contains the following goods:

Class 5: Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the detection, diagnosis and monitoring of cancer.

A statement of use filed on June 17, 2020 meets the minimum filing requirements and has been placed in the child application. The statement of use will be routed to the examining attorney for examination and, if it does not meet all the statutory requirements, the examining attorney will notify the applicant.

37 C.F.R. §2.87; see TMEP §§1110 et seq.

Please call the undersigned with any questions.

Direct questions about this notice to the assigned Intent-to-use staff member below.

/Sykes, Jeffery/

Paralegal Specialist

ITU/ Divisional Unit

(571) 272-4313 Office

jeffery.sykes@uspto.gov

U.S. Trademark Registration No. 88647018 - PYLARIFY - MIN.629.US

To:	Progenics Pharmaceuticals, Inc. (botrademarks@klgates.com)
Subject:	U.S. Trademark Registration No. 88647018 - PYLARIFY - MIN.629.US
Sent:	07/01/20 04:08:26 PM
Sent As:	ecomitu@uspto.gov
Attachments:

United States Patent and Trademark Office (USPTO)

USPTO Official Notice

Office action (Official Letter) or Notice has issued
on 07/01/2020 for
U.S.Trademark Application Serial No. 88647018

Your trademark document has been reviewed by an Intent-to-use staff member. As part of that review, the assigned staff member has issued you an official letter or notice. If a response is required, you must respond by the specified deadline or your application will be abandoned. Please follow the steps below.

(1) Read the official letter or notice.

(2) Direct questions about the contents of the official letter or notice to the assigned staff member identified in the letter. Direct questions about navigating USPTO electronic forms, the USPTO website , the application process, the status of your application, and/or whether there are outstanding deadlines or documents related to your file to the Trademark Assistance Center (TAC).

(3) Response may be required. Carefully review the Office action to determine (1) if a response is required, (2) the applicable response time period, and (3) how to respond using the Trademark Electronic Application System (TEAS). The response must be received by the USPTO before midnight Eastern Time of the last day of the response period.

GENERAL GUIDANCE

Check the status of your application periodically in the Trademark Status & Document Retrieval (TSDR) database to avoid missing critical deadlines.
Update your correspondence email address , if needed, to ensure you receive important USPTO notices about your application.
Beware of misleading notices sent by private companies about your application.
Private companies not associated with the USPTO often use public information provided in USPTO trademark applications to mail and email trademark-related offers and notices-most of which require fees. These companies often have names similar to the USPTO. All official USPTO correspondence will only be emailed from the domain "@uspto.gov." For a current list of companies the USPTO has received complaints about, information on how to identify these offers and notices, and what to do if you receive one, see the misleading notices webpage.